Twist Bioscience Corp
TWST- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001581280
In the last 90 days, Twist Bioscience Corp insiders filed 0 open-market purchases and 33 sales; 341 institutions reported holding it in 13F filings for Q2 2026, worth $7.86B in total; ARK Invest is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 17, 2026, 2:21 AM ET
Revenue flow, FY2026
Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2026: $130.2M (28.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Reported | Nov 12, 2026 | Nov 14, 2025 | Nov 18, 2024 | Nov 17, 2023 | Nov 18, 2022 |
| Revenue | $459.4M | $376.6M | $313.0M | $245.1M | $203.6M |
| Cost of revenue | $218.6M | $185.6M | $179.6M | $155.4M | $119.3M |
| Research and development | $71.8M | $80.3M | $90.9M | $106.9M | $120.3M |
| Selling, general and administrative | $301.2M | $247.0M | $218.4M | $189.7M | $212.9M |
| Operating income | -$139.5M | -$136.3M | -$220.8M | -$217.2M | -$234.8M |
| Interest expense | – | – | – | $5.00K | $80.0K |
| Income tax | $406.0K | $719.0K | $560.0K | $1.15M | -$10.4M |
| Net income | -$130.2M | -$77.7M | -$208.7M | -$204.6M | -$217.9M |
| EPS, basic | $-2.08 | $-1.30 | $-3.60 | $-3.60 | $-4.04 |
| EPS, diluted | $-2.08 | $-1.30 | $-3.60 | $-3.60 | $-4.04 |
| Weighted shares, basic | 62.6M | 59.8M | 58.0M | 56.9M | 53.9M |
| Weighted shares, diluted | 62.6M | 59.8M | 58.0M | 56.9M | 53.9M |
| Margins and growth | |||||
| Operating margin | -30.4% | -36.2% | -70.6% | -88.6% | -115.3% |
| Net margin | -28.3% | -20.6% | -66.7% | -83.5% | -107.0% |
| Revenue growth, year over year | +22.0% | +20.3% | +27.7% | +20.4% | +53.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Reported | Nov 12, 2026 | Nov 14, 2025 | Nov 18, 2024 | Nov 17, 2023 | Nov 18, 2022 |
| Cash and equivalents | $534.0M | $183.0M | $226.3M | $286.5M | $378.7M |
| Short-term investments | $47.9M | $49.4M | $50.1M | $49.9M | $126.3M |
| Accounts receivable | $70.2M | $57.0M | $34.9M | $44.1M | $40.3M |
| Inventory | $46.4M | $28.3M | $24.1M | $32.1M | $39.3M |
| Total current assets | $737.2M | $333.0M | $346.8M | $424.3M | $596.5M |
| Property, plant and equipment | $122.3M | $102.3M | $102.5M | $131.8M | $139.4M |
| Goodwill | $82.2M | $82.2M | $85.8M | $85.8M | $85.8M |
| Intangible assets | $34.2M | $13.4M | $14.5M | $54.5M | $59.7M |
| Total assets | $1.12B | $641.9M | $614.3M | $776.4M | $961.4M |
| Accounts payable | $24.9M | $11.1M | $1.63M | $14.1M | $20.1M |
| Short-term debt | – | – | – | – | $0 |
| Total current liabilities | $125.8M | $91.4M | $71.0M | $73.3M | $90.7M |
| Total liabilities | $233.8M | $168.9M | $141.6M | $153.0M | $172.0M |
| Shareholders' equity | $888.0M | $473.0M | $472.7M | $623.4M | $789.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Reported | Nov 12, 2026 | Nov 14, 2025 | Nov 18, 2024 | Nov 17, 2023 | Nov 18, 2022 |
| Operating cash flow | -$41.4M | -$47.6M | -$64.1M | -$142.5M | -$124.4M |
| Capital expenditures | $47.6M | $28.0M | $5.08M | $27.8M | $101.9M |
| Free cash flow | -$89.0M | -$75.6M | -$69.2M | -$170.3M | -$226.2M |
| Depreciation and amortization | $26.5M | $24.9M | $31.4M | $29.3M | $16.5M |
| Stock-based compensation | $69.9M | $64.5M | $50.9M | $30.3M | $79.7M |
| Investing cash flow | -$53.1M | -$24.8M | -$3.07M | $50.6M | -$232.9M |
| Financing cash flow | $446.7M | $28.5M | $6.89M | $911.0K | $270.5M |
| Net change in cash | $352.2M | -$43.7M | -$60.1M | -$91.0M | -$87.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 15.2% | 17.1% | 16.3% | 12.4% | 39.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 11, 2026 | 68.2M | +11.5% | SEC |
| Jul 29, 2026 | 62.7M | +3.9% | SEC |
| Apr 29, 2026 | 62.3M | +3.9% | SEC |
| Jan 27, 2026 | 61.3M | +2.8% | SEC |
| Nov 13, 2025 | 61.1M | +3.0% | SEC |
| Jul 31, 2025 | 60.4M | +3.0% | SEC |
| May 1, 2025 | 59.9M | +2.9% | SEC |
| Jan 30, 2025 | 59.7M | +3.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.